50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to change the standard of care for patients with blood cancer by engineering hematopoietic stem cells (“HSCs”) to enable the use of targeted therapies post-transplant.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2391% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1870% match
“Our mission is to significantly improve the lives of patients suffering from hematologic diseases by developing differentiated product candidates designed to target fundamental pathways associated with the formation and function of red blood cells.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2670% match
“Our mission is to create new standards of care for patients with cancer.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-0970% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2470% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3070% match
“Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1970% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2469% match
“Our mission is to create life-changing T cell therapies for patients with cancer and autoimmune disorders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0469% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2869% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0768% match
“Our mission is to develop next-generation, potentially curative cell therapies for people with cancer.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1268% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1668% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0268% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0568% match
“Our mission is to revolutionize the treatment of solid tumors with a single dose of engineered TCR T-cells and as a result to address cancers with high unmet needs.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-2468% match
“Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-2068% match
“Our mission is to advance humanity by engineering immunotherapies that are safer, more effective, and broadly accessible.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2868% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2468% match
“Our mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2068% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1267% match
“Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-07-1867% match
“Our mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-1567% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1667% match
“Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1767% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1167% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0867% match
“Our mission is to design, develop and commercialize medical products that enable the collection, processing and cryopreservation of stem cells and other cellular tissues used in the practice of regenerative medicine.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-09-1167% match
“Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune diseases and cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2167% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2867% match
“Our mission is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.”In use 2011 – now·1 sighting·SEC Form S-1, filed 2011-02-0166% match
“Our mission is to build an oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0366% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0966% match
“Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2666% match
“Our mission is to develop next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-11-2866% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2266% match
“Our purpose is to develop and commercialize HSC gene therapies that free patients from a lifetime of genetic disease.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2366% match
“Our mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.”In use 2015 – now·1 sighting·SEC Form S-1, filed 2015-07-2466% match
“Our mission is to transform the lives of patients by creating medicines with improved therapeutic profiles for areas of unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2366% match
“Our mission is to deliver curative, one-time administered genomic medicines that transform the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0266% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1366% match
“Our mission is to transform the lives of patients with rare genetic diseases using our ex vivo autologous HSC gene therapy approach.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2766% match
“Our mission is to transform anemia management in a wide variety of disease states across the globe while improving patients’ lives.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-1766% match
“Our mission is to inspire hope for those battling cancer by expanding on the promise of targeted therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1566% match
“Our mission is to develop new medicines to treat and cure patients with solid tumors using our next generation TIL therapy approach.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2266% match
“Our mission is to harness the evolutionary power of the human immune system to provide patients fighting cancer with safe, effective therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1866% match
“Our mission: Eliminate the organ transplant waiting list We are a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-06-2466% match
“Our mission is to create and advance new medicines for patients suffering from serious and rare diseases that are underserved by today’s therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2666% match
Showing 1–50 of 50